During a media interaction in Pune on 30 August, Cyrus S. Poonawalla, Chairman and Managing Director of Serum Institute of India, said that the company plans to develop dengue cure in approximately 1 year time as the disease is spreading rapidly in India as well as worldwide.

He also said, "After Covishield's success, first time in the world we will be launching malaria vaccine which is desperately needed in the African countries and also in the endemic disease areas of India where hundreds of millions of people are getting affected with malaria."

An insight on this development was earlier shared by Adar Poonawalla, Chief Executive Officer, Serum Institute of India, while speaking with BioSpectrum, that the dengue vaccine in the pipeline is in partnership with the National Institutes of Health (NIH) in the US for which the company is doing a lot of development work in India. Likewise, the process for the malaria vaccine development has also been done in India.

In addition, the company will soon be launching its Human papillomavirus (HPV) vaccine.